key: cord-0802772-lh90i42x
authors: He, Guiqing; Wu, Jing; Shi, Jichan; Dai, Jianyi; Gamber, Michelle; Jiang, Xiangao; Sun, Wenjie; Cai, Jing
title: COVID‐19 in Tuberculosis patients: a report of three cases
date: 2020-04-28
journal: J Med Virol
DOI: 10.1002/jmv.25943
sha: 48a8c31dd93a48a9b9689f2c1d4b38fb73198179
doc_id: 802772
cord_uid: lh90i42x

The clinical features and treatment of pulmonary tuberculosis patients with COVID‐19 is unclear and understudied. Here, three pulmonary tuberculosis patients with COVID‐19 infection were prospectively followed from hospital admission to discharge. We provide information and experience with treatment of pulmonary tuberculosis cases with confirmed COVID‐19 infection. This article is protected by copyright. All rights reserved.

COVID-19 infection were confirmed by a real-time fluorescence polymerase chain reaction assay. All three patients were males, ages 26 to 76 years, and were prospectively followed from hospital admission to discharge. Table 1 illustrates the clinical features, laboratory tests, clinical prognosis, treatments and outcomes of the three patients. According to this epidemiological investigation, all patients were in close contact and infected from others with confirmed infections of COVID-19. Patient 1 and 2 had pulmonary tuberculosis history, and were administered quadruple antituberculosis therapy, while patient 3 had untreated tuberculosis for 50 years. The cavitating lesion of patient 3 in the right upper lobe remained unchanged for many years.

Considering the harmfulness of the SARS-CoV-2 specimen, the hospital restricted the examination of sputum Xpert, T-SPOT.TB and culture of Mycobacterium tuberculosis, etc.

The onset of their symptoms varied from dry cough, chest tightness to persistent fever. Other symptoms included chest pain, diarrhea, and dyspnea. Patient 1 and patient 3, who were of older age, had hypoxemia and developed a critical type and severe type of respectively. Laboratory tests showed all of them had low lymphocyte count and increased levels of CRP, LDH and ESR. Computed tomography scans showed all of the cases presented with multiple bilateral ground-glass opacities and consolidation, with air bronchogram.

All the patients had antivirus therapy including lopinavir, ritonavir, and arbidol with a long prognosis. Patient 1 progressed to respiratory failure type 1 and acute respiratory distress syndrome (ARDS) on Day 10 after onset. He had treatment of noninvasive ventilation support.

with Mycobacterium tuberculosis, whether treated or untreated, a variety of pulmonary and extrapulmonary sequelae and complications can occur, which include bronchiectasis, tracheobronchial stenosis, and broncholithiasis 4 . Structural changes lead to obstructive, restrictive, or mixed patterns of impaired pulmonary function. Studies in patients with pulmonary tuberculosis (PTB) have demonstrated that 33.3-94.0% of such patients develop impaired pulmonary function 5 . The risk factors for TB patients with reduced pulmonary function are having previously had culture-positive PTB, being over 50 years of age, having a low level of education, and having experienced recurrence of tuberculosis 6 . This study suggests that previous lung disease such as treated or untreated mycobacterium tuberculosis (TB) and old age are independent risk factors of a worse prognosis of those infected with COVID-19. Using a glucocorticoid for a short period of time in the early stages of prognosis could reduce the inflammation, but longer-term usage could result in the risk of bacterial infections and abnormal glucose levels. These case reports remind us of the importance of strict isolation of COVID-19 patients, careful use of steroids for their case management, and the possibility of coinfection with TB in COVID-19 patients with incomplete recovery.

The presented case series demonstrates pulmonary tuberculosis patients with COVID-19. In this study, elderly patients with tuberculosis easily progressed to the severe type of COVID-19 and had a long recovery process. These case reports remind us of the possibility of coinfection with TB in COVID-19 patients with incomplete recovery, as well as the importance of careful use of steroids for their case management. 

Statement on the second meeting of the International Health Regulations

Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV)